Bristol bails on ImClone board
Executive Summary
Bristol-Myers Squibb's bid gets even more hostile as representative John Celentano resigns from his position on the ImClone board of directors Sept. 22. Bristol raised its offer to $62 per share on Sept. 22, still a discount over the trading price. Carl Icahn, chairman of the ImClone board, rebuffed the offer in a colorful letter Sept. 23 (1"The Pink Sheet" DAILY, Sept. 23, 2008). The tense situation should come to a head soon; the alternative mystery bidder alluded to by Icahn is slated to finish due diligence Sept. 28 (2"The Pink Sheet," Sept. 15, 2008, p. 10)
You may also be interested in...
War Of The Words Continues As Icahn Responds To Bristol’s Hostile Bid Intent
Unnamed “large pharma’s” due diligence due to complete by Sept. 28, Icahn says.
Mystery Suitor Thwarts Bristol’s ImClone Takeover, Or So Icahn Says
Intrigue surrounding Bristol-Myers Squibb's takeover attempt of its Erbitux (cetuximab) marketing partner ImClone reached new heights with the announcement Sept. 10 that a third-party mystery suitor has stepped in with a white knight bid
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.